Press Releases

03 December 2015

Dr Patrick Vink To Succeed Ian Kent As Non-Executive Chairman

Cambridge, UK – 3rd December 2015: Acacia Pharma Group plc (“Acacia Pharma”), the supportive care company developing products for US and international markets, today announces that Ian Kent will retire as non-executive Chairman on 31st December 2015 and will be succeeded by Dr Patrick Vink.

Patrick Vink most recently served as chief operating officer of Cubist Pharmaceuticals, joining there from senior roles at Mylan Inc., including having global responsibility for the group’s hospital business. Previously Patrick held several leadership positions with Novartis Sandoz, Sanofi and Biogen, principally in global commercial roles. He is also a non-executive director of Inhibikase Inc. and Micreos BV.

Patrick commented “I am delighted to be joining Acacia Pharma at such an exciting time for the company. Under Ian's chairmanship Acacia Pharma has significantly grown in value as its lead pipeline products move through Phase 3 trials towards a potential FDA filing in 2016. I now look forward to working with the Board and the wider Acacia Pharma team on the next stage of the company's evolution.”

Ian Kent added “I am pleased to deliver the chairmanship of Acacia Pharma to Patrick who brings significant senior-level commercial experience to the business as it moves towards its goal of bringing its own products to market. I wish him every success in his role and look forward to hearing of the progress that Julian and his team achieve over the coming years.”

Dr Julian Gilbert, CEO, said: “Both on a personal basis and on behalf of the Board I would like to thank Ian for the advice, support and friendship he has brought in his role as Chairman over the last 7 years and for his enormous contribution to Acacia Pharma’s development. Patrick brings great experience in specialty pharmaceutical companies that we believe will be of great benefit to us and we all look forward to working with him.”

< back to list